Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics

The increasing use of multiple immunomodulatory (IMD) agents for cancer therapies (e.g. antibodies targeting immune checkpoints, bispecific antibodies, and chimeric antigen receptor [CAR]-T cells), is raising questions on their potential immunogenicity and effects on treatment. In this review, we ou...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Davda, Jasmine, Declerck, Paul, Hu-Lieskovan, Siwen, Hickling, Timothy P., Jacobs, Ira A., Chou, Jeffrey, Salek-Ardakani, Shahram, Kraynov, Eugenia
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2019
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6466770/
https://ncbi.nlm.nih.gov/pubmed/30992085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0586-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi